Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma

Cancer Medicine
Hajime SenjoNorth Japan Hematology Study Group (NJHSG)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma. High total metabolic tumor volume (TMTV) calculated using 18 F-FDG PET/CT images at diagnosis predicts poor prognosis of patients with DLBCL. However, high cost and poor access to the imaging facilities hamper wider use of 18 F-FDG PET/CT. In order to explore a surrogate marker for TMTV, we evaluated the correlation between the serum levels of soluble interleukin-2 receptor (sIL-2R) and TMTV in 64 patients with DLBCL, and the results were verified in an independent validation cohort of 86 patients. Serum levels of sIL-2R were significantly correlated with TMTV. ROC analysis revealed that the cutoff value of TMTV ≥150 cm3 or sIL-2R ≥ 1300 U/mL could predict failure to achieve EFS24 with areas under the curve (AUC) 0.706 and 0.758, respectively. Each of TMTV ≥150 cm3 and sIL-2R ≥1300 U/mL was significantly associated with worse 5-year overall survival and event-free survival. Importantly, each of sIL-2R <1300 U/mL or TMTV <150 cm3 identified patients with favorable prognosis among NCCN-IPI high-intermediate and high-risk group. Serum level of sIL-2R represents a convenient surrogate marker to estimate metabolic tumor burden measured by 18 ...Continue Reading

References

May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Oct 2, 2007·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·E Bien, A Balcerska
Dec 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D EnnishiK Hatake
Jan 5, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K MiyazakiS Nakamura
Jun 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tina Marie GreenMichael Boe Møller
Feb 13, 2014·Hematological Oncology·Naoto TomitaYoshiaki Ishigatsubo
Feb 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew J MaurerJames R Cerhan
Jan 21, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CottereauM Meignan
Mar 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne-Ségolène CottereauStéphanie Becker
Jul 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne-Ségolène CottereauStéphanie Becker
Aug 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michel MeignanJudith Trotman
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lasse Hjort JakobsenTarec Christoffer El-Galaly

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

Metavol ®
Metavol

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.